Annovis Bio, Inc.

Recent News

  • Annovis Bio to Present at the Cantor Global Healthcare Conference

    Berwyn, Pennsylvania--(Newsfile Corp. - September 24, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Founder, President and CEO Maria Maccecchini, Ph.D. will present at the virtual Cantor Global Healthcare Conference to be held on September 27-30, 2021.The presentation will be available during a live webcast on Tuesday, September 28 at 11:20am ET, which will later be available...

    2021-09-24 9:00 AM EDT
  • Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

    Berwyn, Pennsylvania--(Newsfile Corp. - September 3, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS), today announced that an interview with CEO and President Dr. Maria Maccecchini, Ph.D. will air on The RedChip Money Report on Bloomberg US on this Saturday September 4th at 7 p.m. Eastern Time. Bloomberg TV is available in an estimated 73 million homes across the...

    2021-09-03 8:30 AM EDT
  • Annovis Bio to Present at Biomarkers for Alzheimer's Disease Summit 2021

    Presentation will highlight positive biomarker data that corroborates the positive efficacy data from two Phase 2 studies of ANVS401Dr. Maccecchini to present virtually, Thursday, August 26, at 1:00 p.m. ETBerwyn, Pennsylvania--(Newsfile Corp. - August 25, 2021) - Annovis, Bio, Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, announced today that Maria Maccecchini, PhD, Founder, CEO and President of Annovis Bio, will present at the Biomarkers for Alzheimer's Disease...

    2021-08-25 8:30 AM EDT
  • Annovis Bio Completes Dosing of Parkinson's Disease Patients with ANVS401 in Phase 2a Clinical Trial

    40 additional patients completed treatmentOn track to disclose final safety and efficacy data in early FallToxic cascade markers expected to be disclosed in two to three monthsPlanning to present all Phase 2a data to the FDA in Q4 2021 and begin Phase 3 in Q1 2022Berwyn, Pennsylvania--(Newsfile Corp. - August 11, 2021) - Annovis, Bio, Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, announced today that the company...

    2021-08-11 8:30 AM EDT
  • Annovis Bio Pleased by Positive Interim Results from Ongoing Phase II Clinical Trials of ANVS401 (Posiphen) for the Treatment of Alzheimer's Disease and Parkinson's Disease

    ANVS401's Interim Clinical Data Demonstrate Statistically Significant Improvements in Cognitive Function in AD Patients and Motor Function in PD PatientsBiomarkers Demonstrate Reduction in Neurotoxic Proteins, Improvement in Axonal Health and Reduction in Inflammation Levels Next Clinical Data Readout Expected in the Third Quarter Berwyn, Pennsylvania--(Newsfile Corp. - July 30, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today said it is pleased by the...

    2021-07-30 10:06 AM EDT
  • Annovis Bio Presents New Clinical and Biomarker Data at 2021 Alzheimer's Association International Conference

    Berwyn, Pennsylvania--(Newsfile Corp. - July 28, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, is presenting new clinical efficacy and biomarker data of its drug ANVS401 during a one hour panel presentation, beginning at 8:00 p.m. ET today,...

    2021-07-28 7:30 PM EDT
  • Annovis Bio to Present New Data at 2021 Alzheimer's Association International Conference

    Berwyn, Pennsylvania--(Newsfile Corp. - July 23, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that it will present new data for its lead product candidate, ANVS401, at the 2021 Alzheimer's Association International Conference (AAIC), which is...

    2021-07-23 8:30 AM EDT
  • Annovis Bio Reports Positive Safety Data from its Phase 2 Alzheimer's Study

    Berwyn, Pennsylvania--(Newsfile Corp. - July 20, 2021) - Annovis Bio, Inc. (NYSE American: ANVS), ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, with data from two phase 2 studies showing its lead compound improves cognition in AD patients and motor function in PD patients, today announced that the Data Safety Monitoring Board (DSMB) has reviewed the safety and tolerability data for Cohort 2 of the Company's Phase 2...

    2021-07-20 8:30 AM EDT